# Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

> **NCT06650423** · — · RECRUITING · sponsor: **Institute of Oncology Ljubljana** · enrollment: 319 (estimated)

## Conditions studied

- Early Breast Cancer
- Hormone Receptor Positive Tumor
- HER2-negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06650423
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-05
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 319 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650423, "Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06650423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*